Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy

xlomafota13 shared this article with you from Inoreader Examination of Necessity for Pelvic Drain Placement After Robot-assisted Radical Prostatectomy Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2895-2899. doi: 10.21873/invivo.12579. ABSTRACT BACKGROUND/AIM: Pelvic drain (PD) placement is commonly performed after robot-assisted radical prostatectomy (RARP), but the need for PD placement is unclear. This study aimed to assess the need for PD placement after RARP. PATIENTS AND METHODS: This retrospective study analysed the effect of PD placement on postoperative complications in patients who underwent RARP between 2009 and 2018. All patients prior to October 1, 2016 had a PD placed; those after did not. RESULTS: Of the 308 study patients, 231 received a PD (PD group) and 77 did not (ND group). The incidence of ileus, urinary tract infection and anastomotic leak did not differ significantly between the groups; nor did the incidence of asymptomatic and symptomatic lymphocele at 2 weeks and 1 year after surgery. Multivariate analysis showed that lymph node dissection is a predictor of asympto matic lymphocele development two weeks after surgery. CONCLUSION: PD placement is not necessary after RARP. PMID:34410984 | DOI:10.21873/invivo.12579 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Moderately Hypofractionated Intensity-modulated Radiotherapy With a Simultaneous Integrated Boost for Locally Advanced Head and Neck Cancer - Do Modern Techniques Fulfil Their Promise?

xlomafota13 shared this article with you from Inoreader Moderately Hypofractionated Intensity-modulated Radiotherapy With a Simultaneous Integrated Boost for Locally Advanced Head and Neck Cancer - Do Modern Techniques Fulfil Their Promise? Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2801-2808. doi: 10.21873/invivo.12566. ABSTRACT BACKGROUND: Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) and moderate hypofractionation offers an opportunity for defining individual doses and a reduction in overall treatment time in locally advanced head and neck cancer (HNSCC). We present retrospective data on toxicity and locoregional control of a patient cohort treated with an IMRT-SIB concept in comparison to normo-fractionated 3D-conformal radiotherapy (3D-RT). PATIENTS AND METHODS: Between 2012 and 2014, 67 patients with HNSCC (stages III-IVB) were treated with IMRT-SIB either definitively or in the postoperative setting. These patients were matched with those of patients treated with normo-fractionated 3D-RT before mid-2012 and their clinical courses were compared. Chemotherapy or cetuximab was given concomitantly in both groups in the definitive situation (po stoperatively, dependent on risk factors). RESULTS: Significantly less toxicity was found in favor of IMRT-SIB concerning dysphagia, dermatitis, xerostomia, fibrosis, and lymphedema. After a median follow-up of 31 months (range=2-104 months), 3-year locoregional control was 73% for those treated with IMRT-SIB versus 78% for those treated with 3D-RT. CONCLUSION: This moderately hypofractionated IMRT-SIB concept was shown to be feasible, incurring less toxicity than conventional 3D-RT. PMID:34410971 | DOI:10.21873/invivo.12566 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Mental Disorders in Nasopharyngeal Carcinoma Patients Receiving Radiation Therapy: A Nationwide Population-based Study

xlomafota13 shared this article with you from Inoreader Mental Disorders in Nasopharyngeal Carcinoma Patients Receiving Radiation Therapy: A Nationwide Population-based Study Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2901-2908. doi: 10.21873/invivo.12580. ABSTRACT BACKGROUND/AIM: Using nationwide data from South Korea, we analyzed the prevalence of mental disorders among patients with nasopharyngeal carcinoma (NPC) who received radiotherapy (RT). PATIENTS AND METHODS: Data were collected between January 2010 and December 2014, and 1,819 patients diagnosed with NPC who underwent RT were identified. We calculated the prevalence of the five most commonly diagnosed mental disorders and their incidences according to a time sequence based on the time of RT. RESULTS: Among 1,819 patients, 144 (7.9%) were diagnosed at least once with a mental disorder between one year before the start of RT and the last follow-up. Based on the first diagnosis, 51 (35.4%) patients experienced anxiety, and 46 (31.9%) suffered from depression. The frequency of mental disorders increased up to the beginning of RT and then declined. Befor e the start of RT, anxiety was most frequent, and depression occurred after the start of RT. The cumulative incidence of mental disorders in the older age group tended to be higher than that of the younger group (≥54 vs. <54 years, log-rank p=0.052). CONCLUSION: The proportion of mental disorders differed before and after the start of RT in patients with NPC. At the beginning of RT, mental disorders emerged most often during management. Early screenings and interventions for mental disorders were able to improve quality of life (QOL). PMID:34410985 | DOI:10.21873/invivo.12580 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Surgical Outcomes in Patients With Centrally Located Non-small Cell Lung Cancer

xlomafota13 shared this article with you from Inoreader Surgical Outcomes in Patients With Centrally Located Non-small Cell Lung Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2815-2820. doi: 10.21873/invivo.12568. ABSTRACT BACKGROUND/AIM: Identification of prognostic factors is helpful in selecting optimal treatment for centrally-located non-small cell lung cancer (NSCLC). This study aimed to detect prognostic factors in patients with centrally-located NSCLC. PATIENTS AND METHODS: NSCLCs in the hilar area requiring pneumonectomy or sleeve lobectomy for complete removal are defined as centrally-located NSCLCs. We retrospectively investigated the clinical courses of 45 patients with such lesions. RESULTS: Sleeve lobectomies were performed on 33 patients and pneumonectomies on 12. Three and five-year survival rates were 72% and 62%, respectively. Presence of comorbidities (p=0.013), severe symptoms (p=0.001), high white cell count (p=0.001), and pathological T3-4 stage (p=0.004) were identified as independent predictors of poor prognosis. Operative procedures did not cor relate with outcomes (p=0.722). CONCLUSION: Presence of comorbidities, severe symptoms, high white cell counts, and pathological T stage are independent predictors of poor prognosis. These data can contribute in selecting appropriate treatments for such lesions. PMID:34410973 | DOI:10.21873/invivo.12568 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prognostic Impact of Sarcopenia in Patients With Biliary Tract Cancer Undergoing Chemotherapy

xlomafota13 shared this article with you from Inoreader Prognostic Impact of Sarcopenia in Patients With Biliary Tract Cancer Undergoing Chemotherapy Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2909-2915. doi: 10.21873/invivo.12581. ABSTRACT AIM: Sarcopenia affects the treatment of various cancer types but its impact on chemotherapy efficacy and prognosis in biliary tract cancer remains unclear. Thus, we evaluated whether sarcopenia independently affects the outcome of chemotherapy for biliary tract cancer. PATIENTS AND METHODS: Data of 50 patients who underwent chemotherapy for biliary tract cancer at two affiliated centres were retrospectively analysed. The association of clinical factors, including sarcopenia, with overall survival and time to treatment failure was analysed. RESULTS: Sarcopenia was an independent factor negatively influencing overall survival and time to treatment failure in univariate and multivariate analyses (median overall survival, sarcopenic vs. non-sarcopenic patients: 10.6 vs. 16.6 months; hazard ratio=2.19, p=0.018; time to treatment failure: 5.3 vs. 13.1 mo nths, hazard ratio=2.50, p=0.019). CONCLUSION: Sarcopenia may affect the efficacy of chemotherapy and prognosis in biliary tract cancer. Thus, improving sarcopenia may improve the prognosis of patients with biliary tract cancer undergoing chemotherapy. PMID:34410986 | DOI:10.21873/invivo.12581 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer

xlomafota13 shared this article with you from Inoreader The Expression of NRIP1 and LCOR in Endometrioid Endometrial Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2631-2640. doi: 10.21873/invivo.12545. ABSTRACT BACKGROUND: The aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. MATERIALS AND METHODS: Immunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates. RESULTS: Endometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was pos itively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67. CONCLUSION: Our study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels. PMID:34410950 | DOI:10.21873/invivo.12545 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Risk Factors for Overall Complications and Remote Infection After Gastrectomy in Elderly Gastric Cancer Patients

xlomafota13 shared this article with you from Inoreader Risk Factors for Overall Complications and Remote Infection After Gastrectomy in Elderly Gastric Cancer Patients Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2917-2921. doi: 10.21873/invivo.12582. ABSTRACT BACKGROUND/AIM: A significant predictive factor for the occurrence of complications after gastrectomy in elderly gastric cancer patients is yet to be determined. We aimed to evaluate the clinical factors associated with overall complications including remote infection after gastrectomy in elderly gastric cancer patients. PATIENTS AND METHODS: We retrospectively analyzed data of 101 patients aged over 80 years, who underwent curative gastrectomy. We analyzed the clinicopathological factors that were independently associated with the occurrence of overall complications or remote infection by a logistic regression model. RESULTS: The overall complication rate was 24.8%. We identified pneumonia as a remote infection, and the occurrence rate of remote infections was 5.9%. On multivariate analysis, hemoglobin (<11 g/dl) and operation time (>240 min) were significantly correlated with the occurrence of overall complications. Regarding the occurrence of remote infection, performing total gastrectomy and a hemoglobin level <11 g/dl were identified as significant risk factors. CONCLUSION: Preoperative anemia and intraoperative factors, including the surgical procedure, could affect the occurrence of postoperative complications in elderly patients. PMID:34410987 | DOI:10.21873/invivo.12582 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model

xlomafota13 shared this article with you from Inoreader Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2661-2667. doi: 10.21873/invivo.12549. ABSTRACT BACKGROUND/AIM: Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disease, and a major challenge for the eradication of CML is to understand the cause of the permanence of minimal residual disease (DRM). This work aimed to induce the maturation of leukemic stem cells with All-trans-retinoic acid (ATRA), making them sensitive to treatment with Imatinib (IM). MATERIALS AND METHODS: K562 cells were treated with IM and with the combined therapy of ATRA together with IM for 48 and 72 h. The expression of BCR-ABL gene and multidrug resistance gene ABCB1 were evaluated using RT-qPCR. RESULTS: The combined ATRA and IM therapy showed a discreet cell differentiation pattern, evidenced by the panoptic morphology analysis at 48 and 72 h of treatment. The BCR-ABL expression showed no statistical difference when treated alone with IM, however in combi nation with ATRA, the expression was statistically significant in 48 and 72 h (p≤0.0001) and when the treatment groups were compared to each other (p≤0.001). The ABCB1 gene expression showed a decrease in isolated IM therapy (p≤0.05) and in the combination in 48 and 72 h (p≤0.0001). CONCLUSION: Combined ATRA and IM therapy was shown to be effective in decreasing BCR-ABL and ABCB1 genes, possibly through the differentiation of blast cells, demonstrating that the therapy could be potentially effective in the blast crisis of the disease and for those patients who develop resistance to available CML treatments. PMID:34410954 | DOI:10.21873/invivo.12549 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Association Between S100b Levels and COVID-19 Pneumonia: A Case Control Study

xlomafota13 shared this article with you from Inoreader Association Between S100b Levels and COVID-19 Pneumonia: A Case Control Study Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2923-2928. doi: 10.21873/invivo.12583. ABSTRACT BACKGROUND/AIM: Extracellular S100b effects are mediated by the receptor for advanced glycation end products (RAGE), which is the S100b membrane receptor. RAGE belongs to the immunoglobulin superfamily of cell surface molecules and serves as a multiligand receptor and is expressed in high abundance by alveolar type I (AT-I) cells in adult pulmonary tissue. This study aimed to provide an insight into the association between the severity of COVID-19 disease and serum S100b levels during admission to the emergency department (ED). PATIENTS AND METHODS: A total of 64 patients (34 mild cases; 30 severe cases) were diagnosed with COVID-19 pneumonia and 30 healthy volunteers were admitted to study. Serum S100b levels were measured by using enzymle linked immunoassay method from blood serum samples. RESULTS: Serum S100b levels showed a significantly higher mean value in mild and severe disease cohorts than in healthy controls (p=0.036 and p=0.028 respectively). Receiver operating characteristic (ROC) analysis indicated greater area under the curve (AUC) for serum S100b levels of the COVID-19 patients (AUC=0.663, 95% CI=0.541-0.785; p=0.014). In addition, serum S100b concentration was measured as 151.7 ng/ml at 79.3% sensitivity and 51.7% specificity (p=0.014). Serum S100b protein levels can serve as a valuable clinical marker in establishing diagnosis of patients. Though not useful in identifying different stages of COVID-19 infection, serum S100b concentration along with other known markers can be utilized to reliably predict clinical severity along with other clinical parameters. PMID:34410988 | DOI:10.21873/invivo.12583 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The Contribution of a Collagen Patch Coated With Fibrin Glue in Sealing Upper Gastrointestinal Defects: An Experimental Study

xlomafota13 shared this article with you from Inoreader The Contribution of a Collagen Patch Coated With Fibrin Glue in Sealing Upper Gastrointestinal Defects: An Experimental Study Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2697-2702. doi: 10.21873/invivo.12553. ABSTRACT BACKGROUND/AIM: We aimed to evaluate the safety and efficacy of sealing primary upper gastrointestinal (GI) perforations with a collagen patch coated with fibrin glue (Tachosil®). MATERIALS AND METHODS: Thirty New Zealand rabbits were used in this study. An iatrogenic gastric perforation was created, and primary repair was performed on the control group. Tachosil®, without suturing the deficit, was used in the intervention group. RESULTS: Leakage was observed in 3 (20%) and 2 rabbits (13.3%) in the control and intervention group, respectively; however, the difference was not statistically significant (p=0.62). Moreover, adhesions formed in 10/15 and all rabbits in the intervention and control group, respectively (p=0.014); however, based on the Zuhlke adhesion's classification, there was no statistically significant differenc e between the two groups. CONCLUSION: A collagen patch coated with fibrin glue is not a replacement but can be considered a safe option for the reinforcement of suturing, preventing leakages in the upper GI tract. PMID:34410958 | DOI:10.21873/invivo.12553 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment

xlomafota13 shared this article with you from Inoreader Successful Conversion Surgery for Advanced Gastric Cancer With Multiple Liver Metastases Following Ramucirumab Plus Paclitaxel Combination Treatment Via In vivo (Athens, Greece) In Vivo. 2021 Sep-Oct;35(5):2929-2935. doi: 10.21873/invivo.12584. ABSTRACT AIM: To present the case of a patient with unresectable gastric cancer showing a remarkable effect by second-line drug treatment with ramucirumab plus paclitaxel and conversion surgery. CASE REPORT: A 68-year-old woman who was diagnosed with gastric cancer was referred to us. Esophagogastroduodenoscopy showed an ulcerated lesion with an irregular nodulated border in the lower third of the stomach, and histology of biopsied specimens indicated a poorly differentiated adenocarcinoma. Enhanced computed tomography revealed extensive invasion of the liver, and the patients was treated using S-1 plus oxaliplatin as first-line chemotherapy. Because she developed liver metastases, the treatment regimen was changed to ramucirumab plus paclitaxel as the second-line treatment. After four cycles of weekly paclitaxel with ramucirumab treatment, the liver metastases ha d completely disappeared. Because no other metastatic lesions in other organs were detected, we performed total gastrectomy with D2 lymphadenectomy. The macroscopic findings of the surgically resected specimen revealed an ulcerated lesion with an irregularly modulated lesion measuring 9.5×4.5 cm. Pathological analysis demonstrated a poorly differentiated adenocarcinoma in the stomach, with invasion to the liver through the serosal layer, and seven lymph node metastases. The postoperative course was unremarkable, and she received ramucirumab in combination with paclitaxel treatment. However, liver metastasis appeared at 4 months after the operation, for which she was treated with irinotecan. Although the patient continued to receive irinotecan chemotherapy for 10 months, her general condition gradually deteriorated, and she was started on best supportive care 13 months after conversion surgery. CONCLUSION: Conversion surgery may prolong survival not only through first-line but also second-line treatments in selected patients with unresectable advanced gastric cancer; however, assessments of additional cases and further studies are required to establish this treatment strategy. PMID:34410989 | DOI:10.21873/invivo.12584 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.